Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Rucksaken, Rucksaka; e; f | Charoensuk, Lakhanawana; e; g | Pinlaor, Porntipb; e | Pairojkul, Chawalitc; e | Khuntikeo, Narongd; e | Pinlaor, Somchaia; e; *
Affiliations: [a] Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand | [b] Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand | [c] Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand | [d] Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand | [e] Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand | [f] Department of Veterinary Technology, Faculty of Veterinary Technology, Kasetsart University, Bangkok, Thailand | [g] Department of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand
Correspondence: [*] Corresponding author: Somchai Pinlaor, Department of Parasitology, Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. Tel.: +66 43 348387; Fax: +66 43 202475; E-mail:psomec@kku.ac.th
Abstract: BACKGROUND: Cholangiocarcinoma (CCA), a malignant tumor of the biliary epithelium, is a tumor with an ineffective diagnosis and poor prognosis. We have previously identified an overexpression of orosomucoid 2 (ORM2) along with CCA development in hamsters using a proteomics technique. OBJECTIVE: To evaluate plasma ORM2 as a candidate risk biomarker for CCA in humans. METHODS: Overexpression of ORM2 in CCA patients was assessed by western blotting and immunohistochemistry. The diagnostic efficacy of ORM2 was investigated in the plasma of patients with hepatobiliary diseases - including 46 cholangitis patients and 70 CCA patients - compared with 20 healthy individuals, using enzyme-linked immunosorbent assay (ELISA). RESULTS: Overexpression of ORM2 was observed in the cytoplasm of bile duct tumor cells and in the adjacent normal hepatocytes at a much higher intensity than in normal bile duct cells. Western blot analysis revealed that its expression was significantly higher in the plasma of CCA patients compared with that of healthy individuals (P < 0.01). ELISA showed that plasma ORM2 levels were significantly elevated in CCA and cholangitis groups compared with healthy individuals (P < 0.0001). The sensitivity and specificity of ORM2 in distinguishing CCA patients from healthy patients were 92.86% and 73.68%, respectively. CONCLUSIONS: Plasma ORM2 could serve as a new risk marker for CCA.
Keywords: Biomarker, cholangiocarcinoma, cholangitis, hepatobiliary disease, orosomucoid 2, ELISA
DOI: 10.3233/CBM-160670
Journal: Cancer Biomarkers, vol. 18, no. 1, pp. 27-34, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl